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Infection with cytomegalovirus (CMV) remains asymptomatic in most immunocompetent
hosts, but is the leading cause of congenital viral infection worldwide and can be life-threat-
ening in immunocompromised individuals. We aimed to assess CMV seroprevalence in a
nationally representative sample of adults in Germany and to identify sociodemographic fac-
tors associated with CMV seropositivity.
Methods
Blood samples from 6552 participants (18–79 years) of the “German National Health Inter-
view and Examination Survey 1998”, a population-based sample of the adult population
in Germany, were tested for the presence of CMV antibodies using an Ig-multiplex assay.
Weighted seroprevalence was calculated and weighted binomial regression was used to
identify factors associated with CMV seropositivity.
Results
Overall CMV seroprevalence was 56.7% (95%CI: 54.8–58.7%), with a higher seropreva-
lence in women (62.3%) than in men (51.0%). Seroprevalence increased with age: from
31.8% to 63.7% in men and from 44.1% to 77.6% in women when comparing the 18–29 with
the 70–79 year age-group, respectively. CMV seroprevalence in women of childbearing age
(18–45 years) was 51.7%. Factors significantly associated with CMV seropositivity were
age, country of birth, smoking status, education, living in northern Germany and number of
household members. In addition, having attended child care was associated with seroposi-
tivity in men, and number of siblings and living in East Germany in women.
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Conclusion
Our results indicate that half the women of childbearing age were susceptible for primary
CMV infection during pregnancy. CMV screening during pregnancy and informing seroneg-
ative women about CMV risk reduction measures could prevent congenital CMV infections
with its serious consequences.
Background
Cytomegalovirus (CMV) is a human herpesvirus which is prevalent worldwide with an esti-
mated seroprevalence of 45% to 100% in the general population [1]. After primary infection
the virus remains latent. Transmission can occur through contact with CMV-infected body
fluids both during primary infection or episodes of reactivation from latency. CMV infections
are usually asymptomatic in immunocompetent hosts but can cause life-threatening complica-
tions in immunocompromised individuals [2]. CMV infection is a major hazard in patients
with AIDS and other immune disorders, transplant recipients, individuals admitted to inten-
sive-care units, and to some extent in elderly people. However, the highest disease burden is
due to congenital CMV infection [2–4]. Worldwide, congenital CMV infection is the leading
cause of neurological damage in children and is associated with growth retardation, hearing
loss, permanent disabilities and microcephaly [5, 6].
Despite this considerable public health burden, few women are aware of congenital CMV
infection [7–9]. Educating women about CMV transmission and preventive hygiene behaviour
can significantly reduce primary CMV infections during pregnancy and thereby congenital
CMV infections [10–14]. A vaccine would be necessary to significantly and permanently
reduce congenital (and other) CMV infections. To date, there is no licensed vaccine available
that protects against CMV. However, several vaccine candidates are currently being tested in
clinical trials [15–17]. A vaccine against CMV was classified as a top priority by "The National
Vaccine Advisory Committee" in the US in 2004, based on the estimation that the disease bur-
den of congenital CMV infection is as high as the disease burden due to congenital rubella
before the introduction of rubella vaccinations [18, 19]. Representative epidemiological data
on the CMV susceptibility of the population are essential for decision making in the fields
of public health and primary prevention through immunization. Since there has been no pop-
ulation-based CMV-specific Ig seroprevalence data available for German adults, the aims of
this study were to estimate CMV seroprevalence in the adult population in Germany and to




The German National Health Interview and Examination Survey 1998 (GNHIES98) was the
first nationwide representative survey on the health status of Germany’s adult population after
the German reunification in 1990. A nationwide two-stage clustered sample design with a
selection of study points was used. The sampling of the 120 study points was done with a prob-
ability proportional to community size and federal state. Persons aged 18–79 years stratified by
sex and age-group from the local population registers were subsequently sampled [20]. The net
sample of the GNHIES98 consisted of 7124 persons (response: 61%) from 120 study points.
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Subjects were eligible if they were familiar with the German language and were able to com-
plete the questionnaires.
Although there was no law or regulation on Ethic Committees in Germany at the time of
the conduct of the study, the study, including the analysis of the CMV-specific Ig data, was
approved by the Board of the Federal Commissioner for Data Protection Berlin, Germany.
The study was conducted according to the Federal and State Commissioners for Data Protec-
tion guidelines. Informed written consent and assent were obtained from all participants and
all data were fully pseudomized before analysis.
Survey methods
In total, 7124 participants were examined at local study centers and blood samples were taken
from a total of 6757 individuals (94.8%). For the study on CMV-specific Ig prevalence, blood
samples of 6552 (92.0%) participants were available. Information on socio-demographic and
lifestyle variables were obtained by standardized self-administered questionnaires. Place of res-
idence was categorized into North, Middle and South Germany (Region I) as well as into for-
mer East and West Germany (Region II). Country of birth was categorized as Germany or
other than Germany. Education was categorized into three levels (low, medium, high) accord-
ing to the “International Standard Classification of Education”. Smoking status was catego-
rized into never smoking, former smoking and current smoking. As a proxy for the number of
children, the number of people under the age of 18 currently living in the household was used,
since there were no data on gravidity or parity available. As a proxy for siblings, the number of
children grown up with was used.
Laboratory methods
Blood samples from the GNHIES98, which were stored at the Robert Koch Institute in Berlin
at -70˚C, were shipped to the German Cancer Research Center (DKFZ) in Heidelberg, Ger-
many. Here, a multiplex serology assay was used to detect CMV-specific IgG, IgM and IgA
simultaneously. Antigen preparation and test methods were previously described elsewhere
[21, 22]. Briefly, plasma samples diluted 1:1000 were tested for antibodies against 4 human
CMV proteins (pp28, pp52, pp65 and pp150) bacterially expressed as glutathione S-transferase
(GST) fusion proteins. The multiplex antibody detection approach was based on a GST cap-
ture immunosorbent assay in combination with fluorescent bead technology (Luminex
Corporation, Austin, Texas) [22, 23]. The seropositivity threshold for each protein was set at a
median fluorescence intensity (MFI) of 150 units and an individual was defined as CMV sero-
positive if two or more CMV-specific proteins were above the threshold. A validation of the
CMV-specific multiplex assay was performed against Enzygnost anti-CMV/IgG and showed
excellent sensitivity and specificity values (Brenner et al. in preparation).
Data analysis
In order to assure that estimates derived from the GNHIES98 study are representative at the
national level, survey weights were applied throughout the statistical analyses which accounted
for the stratified and clustered sample design of the survey [20]. The survey weight takes into
account the region, sex, and age distribution of the population of Germany in the year of the
survey (1998). To ensure representativeness, the subpopulation with available data for CMV
serostatus was compared to the total GNHIES population.
Analyses were conducted in a stratified dataset, in which men and women were analysed
separately to account for gender differences. Univariate analysis was used to identify associa-
tions between sociodemographic factors and CMV seropositivity. Factors that were identified
CMV seroprevalence in Germany
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as possible influencing factors on CMV seropositivity in the literature and with a p-value
<0.20 in the univariate analysis were included in the multivariable weighted binomial regres-
sion model. Interactions between factors were taken into consideration in the multivariable
model. The final multivariable model included all factors that were associated with CMV sero-
positivity at a p<0.05 level in a forward stepwise selection approach. Results were expressed as
weighted crude and adjusted prevalence ratios (PRs) with their 95% confidence intervals (95%
CI). All analyses were done with STATA14.
Results
CMV seroprevalence in the adult population of Germany
The results are based on data from 6552 participants. Characteristics of the study population
are shown in Table 1. The study population was representative of the adult population in Ger-
many with an age range from 18 to 79 years and 51.5% of the participants being female. An
analysis showed no significant differences regarding sociodemographic factors between the
study population and the total GNHIES98 population (N = 7124).
Overall CMV seroprevalence in the adult population of Germany was estimated to be
56.7% (95% CI: 54.8–58.7%). In men, CMV seroprevalence was 51.0% (95% CI: 48.7–53.3%)
and in women 62.3% (95% CI: 59.8–64.6%) Seroprevalence increased with age (Fig 1). In men,
seroprevalence increased from 31.8% (95%CI: 27.3–36.8%) to 63.7% (95% CI: 55.6–71.1%)
when comparing 18 to 29 with 70 to 79 years old individuals. In women, seroprevalence
increased from 44.1% (95% CI: 38.8–49.5%) in 18 to 29 years old women to 77.6% (95% CI:
70.8–83.2%) in 70 to 79 years old women (Fig 1). In all age groups, CMV seroprevalence was
higher in women than in men. Estimated CMV seroprevalence was higher in North Germany
(Men: 52.4%, 95% CI: 48.4–56.5%; Women: 65.6% 95% CI: 61.4–69.6%) than in South Ger-
many (Men: 47.1%, 95% CI: 43.3–51.0%; Women: 57.1% 95% CI: 52.8–61.3%). Total CMV
seroprevalence in women of childbearing age (18–45 years) was 51.7% (95% CI: 47.8–54.3%).
The study population included 34 women pregnant at the time of study participation. Of
these, 13 (34%) were CMV seropositive.
Factors associated with CMV seropositivity
The weighted crude and adjusted PR for men and women can be found in Table 2. In the mul-
tivariable model mutually adjusted for all other variables, the following factors were associated
with CMV seropositivity in Germany in both, men and women: age (PR men: 1.02; women:
1.02), country of birth other than Germany (PR men: 1.76; women: 1.52;), current smoking
(PR men: 1.11; women: 1.11), living in northern Germany (PR men: 1.15; women: 1.11), the
number of household members under the age of 18 years (PR men: 1.09; women: 1.05;), and
the level of education (PR men: 0.82; women: 0.90) (Table 2). Some factors were only associ-
ated with CMV seropositivity either in men or in women: attended child care during child-
hood (PR 0.91) was negatively associated with CMV seropositivity in men only, whereas in
women, the number of siblings grown up with (PR 1.01) and living in East Germany (PR 1.14)
were positively associated with CMV seropositivity. No significant terms of interaction
between variables were identified. Residence in urban or rural regions and working with chil-
dren (e.g. teacher, working in a kindergarten) was not associated with seropositivity in men or
women, neither in uni- nor in multivariable analysis. Some variables that have been shown to
be associated with CMV seropositivity in other studies, such as the number of sexual partners
or income (and thereby socioeconomic status) were not included in this analysis because these
variables were only available for less than 60% of the participants. The number of pregnant
CMV seroprevalence in Germany
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women (N = 34, age 20–41 years, median age 32 years) in this study was too small for further
analysis.
Discussion
This is the first nationwide, representative CMV serosurvey in the adult population of Ger-
many. Although these sera were collected in 1998, this population based CMV seroprevalence
data are an important source for epidemiological modelling and they will serve as baseline
data of longitudinal surveys in the future. In this study, 51% of men and 62% of women were
positive for CMV-specific Ig; these data are comparable to seroprevalence data from France










Sex Male 3172 48.4
Female 3380 51.6
Country of birth German 5769 88.0
Other 606 9.3
Missing 177 2.7
Smoking status Never smoking 2907 44.4
Previous smoking 1395 21.3
Current smoking 2097 21
Missing 153 2.3
Region I in Germany North 1679 25.6
Middle 3008 45.9
South 1865 28.5
Region II in Germany East 2232 34.1
West 4320 65.9




Attended child care Yes 3224 49.2
No 3140 47.9
Missing 188 2.9
No of household members <18 yrs 0 4136 63.1
> = 1 2233 34.1
Missing 183 2.8
No of children grown up with 0 926 14.1
> = 1 5442 83.1
Missing 184 2.8
CMV serostatus Negative 2867 43.3
Positive 3685 56.7
https://doi.org/10.1371/journal.pone.0200267.t001
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Fig 1. Estimated CMV seroprevalence (in percent) and 95% CI in adults in Germany, by age group and sex. In addition, overall
seroprevalence and 95% CI by sex (men = light grey, women = dark grey) are shown on the right. Germany, n = 6552, sera collected 1998–1999.
https://doi.org/10.1371/journal.pone.0200267.g001
Table 2. Results of univariable (crude PR) and multivariable model (adjusted PR) with CMV seropositivity as the dependent variable; data set stratified by gender;
Germany (sera collected 1998–1999, n = 6552).
Variables Men Women
Crude PR (95%CI) Fully adjusted PR (95%CI) Crude PR (95%CI) Fully adjusted PR (95%CI)
Age in years Country of Birth 1.01 (1.01–1.02) 1.02 (1.01–1.02) 1.01 (1.01–1.01) 1.02 (1.01–1.02)
Germany 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Other 1.85 (1.70–2.02) 1.76 (1.62–1.92) 1.50 (1.41–1.60) 1.52 (1.41–1.63)
Smoking status Non-smoking 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Previous smoking 1.27 (1.15–1.42) 1.10 (1.00–1.21) 0.92 (0.84–1.01) 1.02 (0.94–1.11)
Smoking 1.11 (1.00–1.23) 1.11 (1.01–1.21) 0.95 (0.88–1.02) 1.12 (1.04–1.20)
Region I in Germany South 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Middle 1.13 (1.02–1.25) 1.15 (1.05–1.27) 1.13 (1.03–1.23) 1.08(0.98–1.19)
North 1.11 (1.00–1.24) 1.16 (1.04–1.29) 1.15 (1.04–1.27) 1.13 (1.03–1.24)
No of household members <18 yrs 1.03 (0.99–1.07) 1.07 (1.03–1.12) 0.96 (0.92–1.00) 1.05 (1.01–1.09)
Education Low 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Middle 0.74 (0.67–0.81) 0.85 (0.77–0.93) 0.78 (0.73–0.83) 0.92 (0.86–0.98)
High 0.75 (0.66–0.84) 0.82 (0.72–0.92) 0.77 (0.70–0.85) 0.90 (0.82–1.00)
Attended child care No 1 (Ref) 1 (Ref) 1 (Ref) ns#
Yes 0.71 (0.65–0.78) 0.91 (0.83–1.00) 0.81 (0.75–0.87)
Region II in Germany West 1 (Ref) ns# 1 (Ref) 1 (Ref)
East 1.02 (0.93–1.11) 1.15 (1.04–1.19) 1.15 (1.08–1.23)
No of children grown up with 1.07 (1.05–1.09) ns# 1.02 (1.01–1.03) 1.01 (1.00–1.02)
 Mutually adjusted for all other variables in the model,
# ns = Variables were not significantly associated with CMV seroprevalence in the final model and therefore excluded
https://doi.org/10.1371/journal.pone.0200267.t002
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and the Netherlands [24, 25]. In contrast, populations in Portugal (77%), Sweden (83%) and
Croatia (77%) seem to have slightly higher CMV seroprevalence [26–28].
In our study, age and country of birth were the most prominent independent factors associ-
ated with CMV seropositivity as it was shown in studies from other countries [1, 29, 30]. The
increase of CMV seroprevalence with age is well known and results from cumulative exposure
to CMV throughout life. The association between country of birth and CMV seroprevalence
has been shown previously [1, 25, 31, 32]. Seroprevalence differences between countries may
be explained by differences in the prevalence of key exposures related to CMV transmission:
breastfeeding frequency and duration, crowding, childcare arrangements and sexual behav-
iours [1].
CMV seroprevalence is usually higher in women than in men, which indicates that the
exposure to CMV might be partially different between genders. In most publications investi-
gating factors associated with CMV seropositivity, gender is being adjusted for but not ana-
lysed separately. Using the stratified approach for gender the results shown here indicate that
factors associated with CMV seropositivity indeed varied partially between men and women.
The number of siblings was associated with CMV seropositivity only in women and not in
men. One reason may be different playing behaviours and traditional role patterns, with
women having been more involved in caring for their siblings in childhood and therefore
more exposed to CMV shed by young children. In line with the high risk of CMV transmission
from young children, the number of household members under the age of 18 years was associ-
ated with CMV seropositivity. Since the number of children raised was not available, the vari-
able “number of household members under the age of 18 years” was used as a proxy. However,
this proxy probably underestimated the real number of raised children. Young children consti-
tute a well-known source of CMV because they often excrete large amounts of virus in their
saliva and urine for a long time and therefore attending childcare is usually associated with
higher CMV seroprevalence [30, 32, 33]. It is unclear, why in our study having attended child-
care was not associated with CMV seropositivity in women and was associated with lower
CMV seropositivity in men. In the past, child care settings differed in East and West Germany
and also changed over time hindering interpretation. As in other studies, higher education was
inversely associated with CMV seropositivity in this study [24, 25, 32, 34, 35]. Moreover it is
known that smoking has an influence on the immune system and thereby on viral infections
[36]. As in our study, smoking has also been shown to be associated with CMV seropositivity
previously but it is still unclear if smoking has a direct effect on CMV infection or if it is a
proxy for other lifestyle factors [37, 38]. Our results indicate that there were significant
regional differences in the CMV seroprevalence in Germany as has been shown for other
countries [25, 26, 39]. More lifestyle and behavioural data would be necessary to investigate
what causes these regional differences.
In our study 51.7% of women of childbearing age were estimated to be CMV seropositive;
thus, around half of women aged 18 to 45 years were susceptible for primary CMV infection.
However, congenital CMV infections can occur both as a result of primary infection and after
a reinfection or reactivation of latent CMV infection. A meta-analysis of Kenneson et al. esti-
mated that 32% of primary infections and 1.4% of recurrent infections during pregnancy lead
to congenital infection [40]. Due to high CMV seroprevalence globally, seropositive mothers
account for the majority of CMV-induced permanent disabilities in children, even though
the risk for congenital infection is higher in primary infections [40]. However, due to the
relatively low seroprevalence, in Germany primary CMV infections during pregnancy are epi-
demiologically more important than reinfections and reactivation in CMV-seropositive preg-
nant women [41]. In a recent literature review Buxmann et al. estimated that annually 700–
1400 children in Germany suffer from severe permanent disabilities due to congenital CMV
CMV seroprevalence in Germany
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[41]. Primary CMV infection (and probably reinfections) can be reduced significantly if
women are educated about CMV transmission and preventive hygiene behaviours [10–14].
Despite the high disease burden, few women are aware of the risk of congenital CMV infection
and CMV screening is not part of routine antenatal test [7–9, 42, 43]. If informed about pre-
ventive measures, women showed positive attitudes toward CMV prevention behaviours and
perceived them as feasible [8]. These CMV prevention behaviours include washing hands after
exposure to young children’s bodily fluids, not sharing food, cups, or other utensils with chil-
dren, not putting a pacifier in the mouth after it had been in a child’s mouth, and not kissing
children on the lips [8, 14]. The results from this study suggest that many women of child-
bearing age are at risk of primary CMV infection and that there are no easily identifiable high-
risk groups.
To date, there is no vaccine available that prevents primary or reactivation of CMV infec-
tion even though a vaccine would be the best chance to reduce the burden of CMV infection.
However, several vaccine candidates are in clinical development, and a vaccine against CMV
was classified as a top priority by “The National Vaccine Advisory Committee” in the US in
2004 which has triggered commercial interest [15–19]. In order to develop public health rec-
ommendations regarding the use of a CMV vaccine once available in the future, representative
epidemiological data on the susceptibility of the population and the burden of CMV infection
are essential. Since there are no population-based seroprevalence data for CMV antibodies
available for Germany, the present study was conducted. Knowledge about population-based
age-stratified CMV prevalence is necessary for the design of age-specific vaccination strategies
[44]. Therefore population based surveys, such as the GNHIES98, provide useful seropreva-
lence data to be included in transmission models and to inform future vaccination strategies.
Beyond the primary goal of reducing congenital CMV infection, the reduction in CMV trans-
mission achieved by CMV vaccination could have further indirect benefits in terms of lower-
ing CMV incidence in the immunocompromised and the elderly in an ageing population [44].
Meanwhile, CMV screening during pregnancy and educating women about CMV risk reduc-
tion measures could reduce congenital CMV infections with its serious consequences.
CMV seropositivity in our study was measured by GST-based multiplex serology assay
which showed excellent sensitivity and specificity values in a validation study but may not be
identical to estimates measured using other assays. The use of an assay which detects IgG, IgA
and IgM simultaneously achieves high sensitivity but unfortunately it is not possible to analyse
the different Ig-classes separately.
A major strength of this study was the use of a representative population-based sample to
determine CMV seroprevalence. Because of the large sample size and the population-wide
weighted sampling procedure the study also had sufficient statistical power to enable a
reliable multivariable analysis of factors associated with CMV seropositivity. Even though a
weighting factor was used in the analysis and a high response of 61% among eligible persons
was achieved, some bias might be present since institutionalized persons and persons with
inadequate German language skills were excluded. For this reason, the subpopulation of
migrants in this study is not representative for migrants in Germany. In addition, for some fac-
tors, the individual status at the time of the survey may not reflect past exposure.
One important limitation is the age of the data used for this study. The sera were collected
in 1998 and the CMV seroprevalence in the present population in Germany might have
changed since then. Even though it can be assumed that CMV seroprevalence did not change
substantially in the last 20 years (due to the long co-evolution between humans and human
CMV [45]), further seroprevalence studies are necessary to confirm CMV seroprevalence in
the present population in Germany. Due to changing circumstances (German reunification),
lifestyle and behaviours (e.g. higher level of mobility of people moving around Germany,
CMV seroprevalence in Germany
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higher rate of children visiting day-care facilities) might have changed substantially in the pop-
ulation of Germany over the last 20 years which might affect CMV seroprevalence as well.
Especially the immigration of refugees in the recent years should be considered in future sur-
veys. Studies in the US showed no changes in the CMV seroprevalence of the total population,
whereas studies in pregnant women only showed decreasing seroprevalence in Japan and
increasing CMV seroprevalence in Norway [39, 46–48]. Since the participants in GNHIES98
constitute the baseline cohort for health interviews and examinations that were conducted in
2008–2011, the results from this study could also provide an excellent baseline for a longitudi-
nal serosurvey. Longitudinal analysis would be essential to investigate if CMV seroprevalence
changed over the last 20 years and if so which factors were associated with it.
Conclusion
In conclusion, our study constitutes the first population-based seroprevalence data based on a
large sample representative for the adult population living in Germany. These data indicate
that a substantial proportion of women in childbearing age were susceptible to primary CMV
infection. Further seroprevalence studies with more recent data are necessary to evaluate CMV
seroprevalence in the German population and to better understand the epidemiology of CMV
infection. As long as no effective vaccine is commercially available, the primary prevention
measure should be educating women about CMV risk reduction measures.
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